FDA Stalled Sun Protection—For Decades

Americans just got access to a sunscreen ingredient Europe has used for a quarter century—and the real story is how long Washington made us wait for it.

Story Snapshot

The Food and Drug Administration (FDA) finally cleared bemotrizinol, the first new sunscreen active in over 20 years.
Europe approved this broad-spectrum filter around 2000, giving their consumers stronger, more stable protection decades earlier.
FDA scientists now say bemotrizinol is safe and effective for adults and kids 6 months and older at up to 6 percent strength.
The long delay exposes a deeper problem with how America regulates sunscreen like a drug while much of the world moves faster.

A long-awaited ingredient finally crosses the border

Bemotrizinol is a chemical filter that protects skin from both ultraviolet A and ultraviolet B rays, the two main types that drive sunburn, wrinkles, and skin cancer risk. The Food and Drug Administration recently added it to the official list of permitted sunscreen active ingredients, after reviewing data showing broad-spectrum protection, low levels of absorption into the body, and rare irritation in users.^[2]^[5] Dermatology groups had pushed for this move, calling it an important tool to improve real-world sun protection for patients.^[3]

What frustrates many experts is not that FDA checked the science. It is that Europe approved bemotrizinol around 2000, while the United States left it on the sidelines for roughly 25 years.^[3]^[3] During that time, companies in the European Union, Australia, and parts of Asia used it to build sunscreens that hold up better in strong sun and are easier to wear every day.^[6] American shoppers, by contrast, chose from the same old panel of filters last updated in 1999.^[3]

Why bemotrizinol matters more than a new label on the shelf

Bemotrizinol stands out because it is both broad-spectrum and photostable. That means it absorbs a wide slice of ultraviolet light and does not break down quickly once you step into the sun.^[2]^[6] Many older chemical filters lose strength as they absorb light and must be propped up with extra ingredients or frequent reapplication. Clinical data show bemotrizinol at up to 6 percent strength offers strong coverage with only tiny blood levels detected, and side effects were rare and mild.^[2]^[6]

The Food and Drug Administration now calls bemotrizinol “generally recognized as safe and effective” for adults and children six months and older when used as directed.^[2] That status places it alongside zinc oxide and titanium dioxide as a top-tier option in their system.^[3] For consumers, this means the next wave of sunscreens can combine mineral and modern chemical filters to give high protection, feel lighter on the skin, and last longer outdoors without constant reapplication, as long as people still follow label directions.^[5]

How Washington turned sunscreen into a regulatory traffic jam

The long gap between European and American approval did not happen by accident. The United States regulates sunscreen actives as over-the-counter drugs, not as simple cosmetic ingredients. That choice means new filters must clear a high bar for safety and effectiveness similar to other nonprescription medicines.^[5]^[6] Supporters of this model say it protects public health by forcing serious studies on absorption, long-term use, and sensitive groups like children and pregnant women.

The problem is that the system froze. While other markets rolled out modern filters like bemotrizinol and similar broad-spectrum molecules, the Food and Drug Administration did not add a single new ultraviolet filter for more than two decades.^[3]^[6] Researchers in a recent review called this “regulatory inertia” and warned that Americans were stuck with older, less stable options despite global data on newer filters.^[6] Congress later created a new process for nonprescription monograph orders to unjam that pipeline, and bemotrizinol is the first sunscreen active to make it through.^[2]^[6]

Was the long wait caution—or costly overreach?

Defenders of the agency argue the story has a simple answer: better safe than sorry. They point out the Food and Drug Administration now has detailed pharmacokinetic data for bemotrizinol, showing that blood levels rarely exceed its 0.5 nanogram per milliliter threshold and that adverse effects were mostly mild.^[6] From that view, taking years to demand and review rigorous studies before blessing a filter for babies and adults makes sense, given how often people use sunscreen over a lifetime.

🚨 Christopher Bunick, MD, PhD, editor in chief of Dermatology Times, shares his insights on yesterday's FDA approval of #bemotrizinol and what the ingredient's properties mean for OTC sun protection and cosmetic elegance.https://t.co/9Pzy3NzmZw #DermTwitter pic.twitter.com/1gWh1rKJ1b

— Dermatology Times (@DermTimesNow) June 10, 2026

From a common-sense conservative lens, though, the timeline looks far less reasonable. European and Asian regulators saw enough evidence to allow bemotrizinol in everyday products since about 2000, while American families were told to “wait for more data” year after year.^[3]^[6] The end result is that bureaucratic caution, or simple inertia, likely kept many people from access to stronger and more pleasant protection that might have improved real-world sunscreen use. That does not line up with a limited, efficient government that serves citizens first.

What this means for your skin and future sunscreen fights

For ordinary consumers, the practical question is simple: what changes now? The Food and Drug Administration has opened the door, but it is up to manufacturers to launch new formulas, and that can take time.^[5] Expect to see bemotrizinol listed on ingredient panels, often combined with other filters, promoted as “broad spectrum” and “photostable.” For people who burn easily or spend long hours outdoors, these products can offer a meaningful upgrade, as long as they are used generously and reapplied as directed.^[5]

The deeper lesson reaches beyond one ingredient. Bemotrizinol shows both the value and the risk of heavy-handed gatekeeping. Careful review helps catch real safety problems. Yet slow, rigid processes can also deny people better tools for their own health, even when other free nations have used them safely for decades.^[3]^[6] As more next-generation filters line up for review, the question is whether the Food and Drug Administration has truly learned from this 25-year delay—or whether bemotrizinol is just a rare ray of light in a still-cloudy system.